生长抑素联合顺铂抑制卵巢癌细胞的机制研究

Study on the mechanism of Somatostatin combined with cisplatin in inhibiting the ovarian cancer cells

目的研究生长抑素受体在卵巢癌细胞上的表达,探索奥曲肽联合顺铂能否提高对卵巢癌细胞的抑制作用。方法运用RT-PCR法定量测定卵巢癌细胞株OVCAR-3、SKOV-3中SSTR1、SSTR2、SSTR3、SSTR4、SSTR5的mRNA表达;进一步将卵巢癌细胞OVCAR分为空白组、奥曲肽组(浓度分别为1.56、3.13、6.25、12.5、25 mg/L)、顺铂组(1.5 mg/L)以及奥曲肽联合顺铂组,用MTT法检测细胞活性,运用酶标仪492nm测定OD值,计算空白组与各给药组的抑制率(%)。结果 RT-PCR法定量测定结果显示SSTR 5个亚型受体在卵巢癌细胞株OVCAR-3、SKOV-3中均有表达;奥曲肽联合顺铂对卵巢癌细胞OVCAR的抑制率较单独使用奥曲肽或顺铂有所提高,且跟奥曲肽的剂量呈正相关。结论生长抑素受体的5个亚型于卵巢癌细胞株OVCAR-3、SKOV-3均有表达,奥曲肽联合顺铂能提高对卵巢癌细胞的抑制作用,提示其可能通过作用于卵巢癌细胞上生长抑素受体发挥抗癌作用。

Objective To study the expression of the somatostatin receptor SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 in ovarian cancer cells, and explore whether the octreotide in combination with cisplatin can improve the inhibition of ovarian cancer cells, and find new ideas to provide clinical basis for the treatment of ovarian cancer. Methods Using RT-P.CR assay for quantitative determination the expression of SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 mRNA in ovarian cancer cell lines OVCAR-3and SKOV 3. OVCAR cells were divided into four groups ： blank group ; octreotide group （ 1.56 mg/L, 3. 13 mg,/L, 6. 25 mg/L, 12. 5 mg,/L, 25 mg/L respectively） , cisplatin group （ 1.5 mg/L） , octreotide （1.56 mg/L, 3.13 mg/L, 6. 25 mg/L, 12. 5 mg/L, 25 mg/L respectively） unites cisplatin group. The effects on Suppression of ovarian cancer cells were assessed by MTY assay, detecting the OD by ELIASA in 492 nm, to count the suppression ratio of four groups ; Results Quantitative RT-PCR assay determination results showed SSTR1, SSTR2, SSTR3, SSTR4, SSTIL5 receptors are expressed in ovarian cancer cell lines OVCAR - 3 and SKOV 3 ; Octreotide in dose-dependent manner unites cisplatin could promote the effect on suppression of ovarian cancer cell in comparison with using cisplatin independently. Conclusion Somatostatin receptor subtypes can be found in ovarian cancer cell lines OVCAR - 3 and SKOV 3 ; Octreotide in combination with cisplatincan improve the inhibition of ovariancancer cells, the results indicate the octreotide plays a role on inhibiting ovarian cancer cells through somatostatin receptors.